Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Nedaplatin + Gemcitabine for Previously Treated Thymic Carcinoma
jRCTs031180359Phase 2Completed
- Start
- Jan 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nedaplatin and gemcitabine in thymic carcinoma (TC). Primary endpoint: Response rate. Started Jan 2017; status: completed.
02
Drugs
nedaplatingemcitabine
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on jRCTs031180359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180359.